<DOC>
	<DOC>NCT02940639</DOC>
	<brief_summary>A Real-Life Study to Evaluate Efficacy and Safety of Nivolumab in Patients with Advanced Renal Cell Carcinoma after prior therapy.</brief_summary>
	<brief_title>Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced Renal Cell Carcinoma After Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>â‰¥ 18 years diagnosis of advanced RCC (confirmed by histology or cytology) treatment decision to initiate a treatment with nivolumab for the first time for the treatment of RCC (according to the label approved in Germany) has already been taken signed informed consent diagnosis of a cancer other than advanced RCC within the past 5 years, ie, a cancer other than RCC that requires systemic or other treatment. Patients that have been treated curatively more than 5 years ago with no evidence of recurrence and prostate cancer patients in active surveillance can be included previous treatment with nivolumab and/or ipilimumab current active participation in an interventional clinical trial for treatment of their advanced RCC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>